Competing Risk Analysis in Cardiovascular Outcome Trials: A Simulation Comparison of Cox and Fine-Gray Models

summary

The gist

Competing Risk Analysis in Cardiovascular Outcome Trials: A Simulation Comparison of Cox and Fine-Gray Models is a simulation study comparing Cox and Fine-Gray models across various clinically…

In short

This simulation study compared Cox and Fine-Gray models in cardiovascular outcome trials under various conditions. It found that both models generally agree when competing risks are low, but divergence occurs when competing event rates are high or treatment effects are strongly discordant. The paper recommends using simple Cox models for primary analysis in typical settings.

Key concepts

Competing Risk Analysis
This statistical approach is used when more than one event can happen at the same time, and only one outcome is of interest. In cardiovascular trials, this means a patient could die from the primary condition or a competing condition (like cancer) during follow-up. The models help estimate the risk of the main event while accounting for these other possible events.
Cox Model
The Cox proportional hazards model is a standard survival analysis tool used to assess how treatment affects survival time. It treats competing events as censored, meaning it assumes that if a patient experiences a competing event, they are no longer at risk for the primary event. It provides clear and interpretable results in many trial settings.
Fine-Gray Model
The Fine-Gray model is an alternative survival analysis method specifically designed to handle competing risks by estimating the subdistribution hazard. This model is useful when you want to analyze the risk of a specific event occurring before any other event, rather than just censoring patients due to a competing risk.
Marginal Hazard Ratio
This refers to the true effect of treatment on the primary outcome if there were no competing risks. The study found that neither the Cox nor Fine-Gray models consistently recovered this true value under most conditions, suggesting caution when interpreting results in complex scenarios.

Terminology used across episodes

This episode discusses

The paper

Competing Risk Analysis in Cardiovascular Outcome Trials: A Simulation Comparison of Cox and Fine-Gray Models · Read on arXiv

Tuo Wang, Yu Du

Global Statistical Sciences, Eli Lilly and Company

Transcript

Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.

Tom: We're looking at the paper: "Competing Risk Analysis in Cardiovascular Outcome Trials".

Jane: Here's the gist of the paper. Competing Risk Analysis in Cardiovascular Outcome Trials: A Simulation Comparison of Cox and Fine-Gray Models is a simulation study comparing Cox and Fine-Gray models across various clinically relevant scenarios to understand when they yield concordant versus divergent estimates, providing practical guidance in cardiovascular outcome studies<ref:2602.16031.arXiv:2602.16031v1

stat.ME: 5>.

Tom: Methodological Setup The study conducts Monte Carlo simulations generating correlated time-to-event data using bivariate copula models<ref:2602.16031.arXiv:2602.16031v1

stat.ME: 5>.

Jane: The joint survival function is defined by the equation S(t1, t2Z = z) = exp(-

(θz 1 · λ 1 · t 1)α + (θz 2 · λ 2 · t 2)α: 1/α)<ref:2602.16031.arXiv:2602.16031v1

stat.ME: 5>.

Tom: Data generation involves randomization, generating correlated uniform variables via Gumbel-Hougaard copula, and transforming these into event times T1i and T2i<ref:2602.16031.arXiv:2602.16031v1

stat.ME: 5>.

Title and authors: Tom: We just talked about the title and authors of this paper, "Competing Risk Analysis in Cardiovascular Outcome Trials: A Simulation Comparison of Cox and Fine-Gray Models," and how it sets up a simulation to compare the Cox model against the Fine-Gray model to see when their results agree or disagree.

Jane: That comparison is key because in cardiovascular trials, we often have two things happening at once, like a patient dying from their heart disease and then dying from another cause while they're still being watched. The title tells us the paper is about figuring out which statistical model to trust when that happens.

Lu: The authors are Tuo Wang and Yu Du from Global Statistical Sciences at Eli Lilly and Company, Indiana, United States. They set up a Monte Carlo simulation using bivariate copula models to generate correlated time-to-event data to test these two approaches across various clinically relevant scenarios.

Meng: It’s interesting that they are simulating the varying competing event rate between zero point five percent and five percent annually, which gives us a wide range of risk levels to test against their models.

Lalam: They specifically vary the treatment effect on the competing event, theta two, from zero point five reduction to one point five increase in hazard. That means they are testing scenarios where treatment helps with the competing event and scenarios where it hurts it too.

Jane: So, when we look at this simulation study, what is the main takeaway for us? Is there a clear answer about which model to use in a real trial right now?

Tom: The main message is that the choice between Cox and Fine-Gray models matters primarily when competing event rates are high and treatment effects are directionally discordant. It’s not some simple rule for every situation.

The paper's summary: Tom: So, summarizing the study, they set up this comparison to see if we get consistent results when we change the inputs—like how fast the competing events happen or how strong the treatment effect is on those events.

Jane: They found that in most standard cardiovascular trials, especially those with about one percent annual non-CV death rate, both Cox and Fine-Gray models give very similar estimates on average.

Lu: That similarity is what they report when a typical CVOT setting has non-CV death rates of approximately one percent annually, the two methods produce very similar estimates on average.

Meng: It means that for the vast majority of standard cardiovascular trials, you can use the simpler Cox proportional hazards model treating competing events as censored without major issues for your primary analysis.

Lalam: They also mentioned that they tested whether the correlation between primary and competing events was a driver of divergence, and it turns out that correlation matters when those other factors are already pushing things away.

Jane: So, the comparison isn't just about which model is "better," but figuring out exactly what causes those two models to give different answers.

The paper's improvements: Tom: The authors suggest that for supplementary descriptive analysis, cumulative incidence using the Aalen-Johansen estimator can provide transparency about the impact of the competing risk.

Lu: They also point out that when marginal causal effects are the target of inference, alternative approaches are motivated when both standard methods fail to recover consistent estimates.

Meng: Specifically, they suggest things like inverse probability of censoring weighting or multistate models as options for complex analyses when seeking that marginal causal treatment effect.

Jane: And they also mentioned including all-cause mortality in the composite endpoint as another alternative that sidesteps competing risk complications entirely by capturing the full mortality benefit.

Tom: But we need to be careful about what these alternatives do, because neither Cox nor Fine-Gray consistently recovers the true marginal hazard ratio under most scenarios with non-negligible competing risks.

Lu: The bias is minimal when the treatment effect on the competing event theta two is similar to the treatment effect on primary events theta one, which is zero point eight zero regardless of competing event rate or correlation structure.

Meng: So, if you're aiming for that true marginal hazard ratio of zero point eight zero, you have to be careful because it only works under very specific conditions.

Conclusion: Jane: So to wrap up this whole discussion on the "Competing Risk Analysis in Cardiovascular Outcome Trials: A Simulation Comparison of Cox and Fine-Gray Models," what’s the final word?

Tom: The concordance of Cox and Fine-Gray methods in typical CVOT settings—where competing event rates remain at approximately one percent—provides reassurance that analytical approach selection has limited impact on trial conclusions under those conditions.

Lu: That reassurance is important, but the paper also says that pre-specified Cox models should not be abandoned post-hoc simply because competing risks appear relevant after unblinding data.

Meng: Also, the Fine-Gray model doesn't constitute proper sensitivity analyses to Cox models per ICH E9(R1) because they target different estimands rather than testing assumptions of the same estimand.

Lalam: And they strongly support continuing the use of interpretable Cox proportional hazards models as the primary analytical approach for most CV outcome trials.

Jane: So, to summarize, the choice between methods matters when competing event rates are high and treatment effects are directionally discordant; otherwise, sticking with the simpler Cox model is usually the best path forward.

Tom: That’s right. This study gives us evidence to inform trial design, protocol development, statistical analysis planning, and regulatory discussions around competing risk methodology.

Lu: And for future work, they suggest looking into inverse probability of censoring weighting or multistate models when those standard methods fail to recover consistent estimates for marginal causal treatment effects.

Meng: And we’re always watching that high competing event rate scenario—exceeding five percent annually combined with highly discordant treatment effects where theta two is one point zero—because that’s the tipping point.

Lalam: That's all we have from this paper for now on this topic.

More episodes

← Home